(Q38014367)

27 August 2017

title

New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies (English)

1 reference

27 August 2017

1 reference

1 reference

head and neck carcinoma

1 reference

1 reference

Edward Li

1

1 reference

27 August 2017

James A Trovato

series ordinal

2

1 reference

27 August 2017

publication date

1 June 2012

1 reference

American Journal of Health-System Pharmacy

27 August 2017

published in

1 reference

27 August 2017

volume

69

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1031-1037

1 reference

The burdens of cancer therapy

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Updated clinical practice guidelines for the prevention and treatment of mucositis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Putting evidence into practice: evidence-based interventions for the management of oral mucositis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Recent advances in head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Palifermin for oral mucositis after intensive therapy for hematologic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received ca

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Mucositis: The impact, biology and therapeutic opportunities of oral mucositis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

mTOR inhibitor-associated dermatologic and mucosal problems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

The emerging role of lapatinib in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Oral complications of targeted cancer therapies: a narrative literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP100531

31 March 2020

Identifiers

DOI

10.2146/AJHP100531

1 reference

27 August 2017

1 reference